Qazi F, McGuire W P
Division of Hematology/Oncology, Emory University School of Medicine Atlanta, Georgia.
CA Cancer J Clin. 1995 Mar-Apr;45(2):88-101. doi: 10.3322/canjclin.45.2.88.
The treatment and long-term survival of patients with ovarian cancer varies by stage. At present, five-year survival for patients with early-stage disease ranges from 50 to 95 percent, while five-year survival for patients with advanced-stage disease is less than 25 percent. Several new drugs with significant activity in advanced-stage ovarian cancer offer hope for increased long-term survival in the future. This article reviews the current and experimental approaches to the treatment of all stages of ovarian cancer.
卵巢癌患者的治疗方法和长期生存率因疾病分期而异。目前,早期卵巢癌患者的五年生存率在50%至95%之间,而晚期患者的五年生存率则低于25%。几种对晚期卵巢癌具有显著活性的新药为未来提高长期生存率带来了希望。本文综述了卵巢癌各阶段治疗的现有方法和实验方法。